Daily BriefsJapan

Daily Brief Japan: Lasertec Corp, Mercari , ZOZO Inc, Integral Corporation, Shiseido Company, Seven & I Holdings, Medipal Holdings, SBI Sumishin Net Bank, Ohba Co Ltd and more

In today’s briefing:

  • September Nikkei 225 Review – Lasertec, Mercari, Nitori IN, Expected DELETEs Out (Matsui the Biggie)
  • Nikkei 225 Index Rebalance: Mercari, Lasertec, Nitori IN; Nippon Glass, Mitsui E&S, Matsui Sec OUT
  • March 2024 Nikkei 225 Rebal – Look for Zozo, Ryohin Keikaku, and Maybe a Socionext Split
  • Integral Corporation IPO: New Price Range Is Tempting
  • Integral Corporation Pre-IPO – Thoughts on Valuation
  • Japanese Cosmetics Ready to Blossom with Asian Visitors
  • Bargain Sale at Sogo Seibu as Seven & I Finally Capitulates
  • Medipal Holdings (7459 JP): Started FY24 On a Strong Note with Accelerated Revenue
  • SBI Sumishin Net Bank – Dramatic ROA Expansion, Steady & Strong, Profit & Loan Growth, ROE at 19%
  • 4Q Follow-Up – Ohba (9765 JP)


September Nikkei 225 Review – Lasertec, Mercari, Nitori IN, Expected DELETEs Out (Matsui the Biggie)

By Travis Lundy


Nikkei 225 Index Rebalance: Mercari, Lasertec, Nitori IN; Nippon Glass, Mitsui E&S, Matsui Sec OUT

By Brian Freitas


March 2024 Nikkei 225 Rebal – Look for Zozo, Ryohin Keikaku, and Maybe a Socionext Split

By Travis Lundy


Integral Corporation IPO: New Price Range Is Tempting

By Arun George


Integral Corporation Pre-IPO – Thoughts on Valuation

By Sumeet Singh

  • Integral Corporation (5842 JP) is looking to raise around US$123m in its Japan IPO.
  • Integral is a private equity management company advising funds that invest in both listed and unlisted companies in Japan, with a focus on mid-sized companies.
  • In our previous notes, we looked at the company’s past performance. In this note, we talk about valuation.

Japanese Cosmetics Ready to Blossom with Asian Visitors

By Oshadhi Kumarasiri

  • Despite expected increased demand from returning Asian tourists, Japanese cosmetics companies have been hesitant to revise their 2H 2023 inbound demand projections.
  • We are long Kose Corp (4922 JP), Shiseido Company (4911 JP), and Pola Orbis Holdings (4927 JP), as consensus estimates look extra cautious and reasonable and appealing FY+2 valuation multiples.
  • We view the risk of Chinese consumers boycotting Japanese cosmetics due to Fukushima wastewater release as relatively low.

Bargain Sale at Sogo Seibu as Seven & I Finally Capitulates

By Michael Causton

  • Seven & I has finally sold Sogo Seibu to Fortress Investments.
  • It will be pleased to have offloaded a loss-making format it never really understood but at a cost – it will write off more than ¥90 billion in loans.
  • Fortress will immediately sell the land under Seibu Ikebukuro and some other assets to Yodobashi with suggestions of major redevelopment of both Ikebukuro and Shibuya.

Medipal Holdings (7459 JP): Started FY24 On a Strong Note with Accelerated Revenue

By Tina Banerjee

  • Medipal Holdings (7459 JP) announced strong Q1FY24 result, with a 6% YoY revenue growth to ¥887B, driven by growth across all three business segments.
  • However, operating profit declined 8% YoY to ¥12B, mainly due to increase in SG&A expenses. Driven by an extraordinary income of ¥3.3B, net profit jumped 35% YoY to ¥11B.
  • The company has reaffirmed FY24 guidance, which calls for a 4.5% YoY revenue growth, flat operating profit, and a 9.3% YoY decline in net profit.

SBI Sumishin Net Bank – Dramatic ROA Expansion, Steady & Strong, Profit & Loan Growth, ROE at 19%

By Daniel Tabbush

  • This is not a typo: SBI Sumishin Net Bank saw loans up 21% YoY in 1Q24, operating in Japan
  • The bank has achieved cost scale, with acquisition cost per account a fraction of 2 yrs ago
  • Credit quality remains exceptional, amongst best in Japan, with 0.06% NPL ratio in 1Q24

4Q Follow-Up – Ohba (9765 JP)

By Sessa Investment Research

  • Since reporting its full-year results for FY23/5, OHBA shares have been rerated and its share price is up approximately 20% at the time of writing.
  • In its five-year medium-term management plan ending in FY28/5, the company has set ambitious earnings targets (sales CAGR of 5.0%, operating profit CAGR of 7.0%) and a policy committed to capital efficiency (ROE 12%, ROIC 12%).
  • In addition, the company has further strengthened its shareholder return policy (targeting a total return ratio of 60%), which has been one of the best among listed construction consulting companies, and this has likely driven the rerating to some extent.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars